expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these assumptions will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, prolonged impairment of sales from changes in our sales organization, potential difficulties hiring sales personnel with the desired qualifications, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
MacDougall Biomedical Communications
781-235-3060--Financial Tables to Follow--SERACARE LIFE SCIENCES, INC.STATEMENTS OF OPERATIONS — UNAUDITEDFor the Three Months EndedFor the Six Months EndedMarch 31,March 31,2011201020112010Revenue
$ 11,002,884$ 12,851,370$ 21,465,381$ 24,108,475Cost of revenue
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE SeraCare Life Sciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors2
. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing3
. SeraCare Reports First Quarter Fiscal Year 2011 Results4
. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 20115
. SeraCare Life Sciences Secures $20 Million Credit Facilities6
. PharmAthene Reports First Quarter 2011 Financial and Operating Results7
. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR8
. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results9
. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update10
. GenVec Reports First Quarter 2011 Financial Results11
. American Oriental Bioengineering Reports First Quarter 2011 Financial Results